Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018452 | 1.00 | SLC6A4 (0.37) | SLC6A4IDO1OPRM1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL27164845 | 0.98 | SLC6A4 (0.36) | SLC6A4IDO1OPRM1ALDH1A1HTT | |
| SCHEMBL16447921 | 0.84 | IDO1 (0.32) | IDO1OPRM1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18793288 | 0.82 | SMN1; SMN2 (0.34) | IDO1OPRM1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21164273 | 0.79 | ALDH1A1 (0.33) | IDO1OPRM1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24919732 | 0.78 | ALDH1A1 (0.36) | IDO1OPRM1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15304182 | 0.78 | ALDH1A1 (0.36) | IDO1OPRM1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2303823 | 0.77 | — | — | |
| SCHEMBL28802900 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL28803076 | 0.75 | HRH3 (0.33) | IDO1ALDH1A1HTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | SLC6A4 4396/4885IDO1 166/4885OPRM1 1500/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | SLC6A4 4328/4885IDO1 55/4885OPRM1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.